Becker's Healthcare October 23, 2024
The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.
The approval is based on data from Pfizer’s Phase 3 MONeT trial, which evaluated the vaccine’s safety and efficacy in high-risk adults, according to an Oct. 22 news release from...